Variant Anti-Viral Polypeptides

The USPTO published patent application US20260092088A1 for variant lectin anti-viral polypeptides on April 2, 2026. The application (No. 19112643) covers compositions and methods for using variant lectin molecules in the treatment and prevention of viral diseases in animals. CPC classifications include C07K 14/405, A61P 31/14, C12P 21/005, and A61K 38/00.\n\nThis is a routine patent application publication with no compliance obligations or deadlines. No specific action is required from competitors or industry parties. However, companies developing anti-viral therapeutics may wish to review the claims for potential freedom-to-operate concerns. No penalties or enforcement consequences apply to this document.